gm-ct-01
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2003 (NCT00054977)
Timeline
Indications
Mechanism of action
- Galectin-1INHIBITOR
LGALS1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gm-ct-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01723813 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2012 | Université catholique de Louvain |
| NCT00388700 | Phase 2 | Oct 1, 2006 | Galectin Therapeutics Inc. |
| NCT00386516 | Phase 2 | Sep 1, 2006 | Galectin Therapeutics Inc. |
| NCT00110721 | Phase 2 | May 1, 2005 | Galectin Therapeutics Inc. |
| NCT00054977 | Phase 1 | Feb 1, 2003 | Galectin Therapeutics Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. | For profit | 4 | 4 | 2 | 2003 |
| Université catholique de Louvain | Academic/Hospital | 1 | 1 | 1 | 2012 |
2 organizations
Page 1 / 1